Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: clinical trials + clinical trial + natrecor  Related to the article below (Last Update: 7/8/2008)

Resverlogix to Collaborate with Cleveland Clinic
FOXBusiness - Jun 19, 2008
In the case of Resverlogix's 2b clinical trial it will be used to assess the amount of disease present prior to the administration of RVX-208 to subjects as ...TSE:RVX
Is Merck Flying Blind?
Forbes, NY - Jun 20, 2008
Last November, Forbes was first to report that a clinical trial of Vytorin had been delayed an unusual 18 months. The results were released in January, ...MRK - OTC:RHHBY - SGP
Source: Google News

… natriuretic peptide) in heart failure A randomized, double-blind, placebo-controlled clinical trial -
RM Mills, TH LeJemtel, DP Horton, C Liang, R Lang, … - Journal of the American College of Cardiology, 1999 - Am Coll Cardio Found
... Clinical trial design. The design of this trial required a trade-off between ... likely
underestimate the sustained hemodynamic benefits of nesiritide because of ...

… With Nesiritide for Decompensated Heart Failure A Pooled Analysis of Randomized Controlled Trials -
JD Sackner-Bernstein, M Kowalski, M Fox, K … - JAMA, 2005 - Am Med Assoc
... the US Food and Drug Administration (FDA), the study sponsor (Scios Inc), a PubMed
literature search using the terms nesiritide, clinical trials, and humans ...

Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart … -
JD Sackner-Bernstein, HA Skopicki, KD Aaronson - Circulation, 2005 - Am Heart Assoc
... infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a
randomized, double-blind, placebo-controlled clinical trial: Natrecor Study Group ...

Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart …
WS Colucci, U Elkayam, DP Horton, WT Abraham, RC … - N Engl J Med, 2000 - ncbi.nlm.nih.gov
... In the comparative trial, the improvements in global clinical status, dyspnea, and
fatigue were sustained with nesiritide therapy for up to seven days and were ...

… serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial) -
CW Yancy, MT Saltzberg, RL Berkowitz, B Bertolet, … - The American Journal of Cardiology, 2004 - Elsevier
... 1 , 2 , 3 , 4 , 5 , 6 and 7 Nesiritide has been well tolerated in controlled clinical
trials involving >1,200 patients with HF, and prospective randomized ...

Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the … -
AJ Burger, DP Horton, T LeJemtel, JK Ghali, G … - American Heart Journal, 2002 - pt.wkhealth.com
... In this randomized, multicenter trial, we compared the safety and clinical
effectiveness of the cardiac hormone nesiritide (human B-type natriuretic peptide ...

[CITATION] … natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial
RM Mills, TH LeJemtel, DP Horton? - J Am Coll Cardiol, 1999

Nesiritide for the treatment of decompensated heart failure -
WS Colucci - Journal of Cardiac Failure, 2001 - Elsevier
... Continuous infusion. Most subsequent clinical trials with nesiritide have
used a continuous infusion. In an early study, Marcus et ...

Overview of Randomized Clinical Trials in Acute Heart Failure Syndromes -
JR Teerlink - The American Journal of Cardiology, 2005 - Elsevier
... However, in multiple clinical trials, nesiritide has been demonstrated to be
efficacious in decreasing PCWP and improving patient symptoms. 7 , 25 and 26. ...

Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with … -
A Nohria, SW Tsang, JC Fang, EF Lewis, JA Jarcho, … - Journal of the American College of Cardiology, 2003 - Am Coll Cardio Found
... Clinical assessment and follow-up of functional ... 54[CrossRef][Medline]; CONSENSUS
Trial Study Group. ... Intravenous nesiritide versus nitroglycerin for treatment of ...

Source: Google Scholar
 
 

Natrecor, clinical trials show increased mortality

 
 
Scios and FDA notified HealthCare Professionals of revisions to the Adverse Reactions / Effect on Mortality section of the prescribing information for Natrecor ( Nesiritide ).


There have been several published reports about Nesiritide, a treatment for patients with acutely decompensated congestive heart failure ( ADHF ) with dyspnea.

These reports raise the question of whether Nesiritide may have adverse effects on survival and kidney function compared to control agents ( generally Nitroglycerin and diuretics ).

Nesiritide is an effective drug with a well-described safety profile for patients requiring intravenous treatment for acutely decompensated congestive heart failure with dyspnea at rest or with minimal activity.
Heart failure affects about 5 million Americans, and ADHF is a life-threatening condition for which there are limited treatment options. Advanced ADHF patients have a 30% risk of mortality within one year.
Nesiritide was approved for the treatment of advanced ADHF on the basis of its ability to improve dyspnea and reduce pulmonary capillary wedge pressure. In these studies the mortality was somewhat greater in the Nesiritide group than in the comparator groups and this has been noted in labeling since Natrecor was first marketed.
It was not clear that the small increase was drug related.

Updated labeling for Natrecor was approved recently based on ongoing discussions with the U.S. Food and Drug Administration.
The revised label language is based on the analyses of survival data from seven controlled studies, including the three studies used in the meta-analysis that recently appeared in JAMA.
The label now includes 30-day mortality data in addition to the 180-day data that previously appeared in label.
The analyses show a nominal increase in mortality, but the increases are not statistically significant, and thus remain of uncertain clinical significance.

In seven clinical trials ( 1700 patients ), the 30-day mortality rate is 5.3% in the Nesiritide treatment group as compared with 4.3% in the group treated with other standard medications.
In four out of these seven clinical trials where it was measured, the 180-day mortality rate is 21.7% in the Nesiritide treatment group as compared with 21.5% in the group treated with other standard medications. None of these mortality differences reached statistical significance. As described in the revised labeling, “ There were few deaths in these studies, so the confidence limits around the hazard ratios for mortality are wide.
The studies are also small, so some potentially important baseline imbalances exist among the treatment groups, the effects of which cannot be ascertained.”

Recent news focused on a meta-analysis published in JAMA regarding the potential risk of mortality associated with the use of Natrecor.
The same author published another meta-analysis that focused on the renal effects of Natrecor in the March 29 th issue of Circulation.

The JAMA meta-analysis is a three-study subset of the original clinical research on Natrecor.
The authors state that this meta-analysis is hypothesis generating only, and the observed differences were not statistically significant.
Eugene Braunwald, distinguished Hersey Professor of Medicine, Harvard Medical School, and Chairman of TIMI Study Group at Brigham and Women’s Hospital in Boston, has agreed to convene a panel of external experts to review all available studies.

Source: Scios, 2005
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 © 2002-2006

Keywords::

Contact Iconocast

Home Page